China Oncology Drug Innovation Not Correlating With Clinical Benefit
While China approved a record number of innovative oncology drugs in 2021, the correlation between their novel mechanisms of action or targeted indication and clinical benefit is not statistically insignificant, a well-known researcher claims in a new report.
You may also be interested in...
China has emerged as a major new force in global pharma R&D amid a "boom" in activity, with not one but two of its companies entering the top 25 by pipeline size for the first time.
China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.